Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.

Antimicrobial agents and chemotherapy - 18 Oct 2022

Yamada Walter, Kim Sarah, Almoslem Mohammed, Kim Soyoung, Myrick Jenny, Nole Jocelyn, Duncanson Brandon, Louie Arnold, Peloquin Charles A, Schmidt Stephan, Drusano George L, Neely Michael

Abstract excerpt

Mycobacterium tuberculosis (Mtb) exists in various metabolic states, including a nonreplicating persister (NRP) phenotype which may affect response to therapy. We have adopted a model-informed strategy to accelerate discovery of effective Mtb treatment regimens and previously found pretomanid (PMD), moxifloxacin (MXF), and bedaquiline (BDQ) to readily kill logarithmic- and acid-phase Mtb. Here, we studied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Moxifloxacin

Share to Mycobacterium tuberculosis

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 36165631
DOI: 10.1128/aac.00695-22
PMCID: PMC9578415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.PMID 36165631Read ↗

Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection ModelSemantic proximity Read ↗

Targeting Phenotypically Tolerant Mycobacterium tuberculosisSemantic proximity Read ↗

Assessing the propensity of TB clinical isolates to form viable but non-replicating subpopulations.Semantic proximity Read ↗

Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We StandSemantic proximity Read ↗

Strain diversity drives heterogeneous responses to tuberculosis combination therapySemantic proximity Read ↗

Elucidating population-wide mycobacterial replication dynamics at the single-cell levelSemantic proximity Read ↗

The identification Mycobacterium tuberculosis genes that modulate long term survival in the presence of rifampicin and streptomycinSemantic proximity Read ↗

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.Semantic proximity Read ↗

Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosisSemantic proximity Read ↗

<scp>TB</scp> drug development: immunology at the tableSemantic proximity Read ↗

Mycobacterial biofilms: A therapeutic target against bacterial persistence and generation of antibiotic resistanceSemantic proximity Read ↗

De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.